Shanghai-based Xin Weisheng and India’s Nandani Medical Laboratories have partnered to enhance pharmaceutical quality control through advanced AI-driven visual inspection systems. The collaboration delivers a 70% improvement in defect detection efficiency at speeds up to 600 bottles per minute, strengthening scalable quality assurance aligned with global regulatory standards.

Shanghai innovator Xin Weisheng is advancing pharmaceutical quality standards in India by deploying AI-enabled visual inspection systems at Nandani Medical Laboratories. This strategic partnership underscores both companies’ commitment to intelligent pharma solutions and global compliance.

Nandani, a WHO-GMP and ISO-certified manufacturer of injectable formulations, serves domestic and international markets with a focus on quality and regulatory confidence. Since integrating Xin Weisheng’s automated inspection technology in 2019, Nandani has achieved a significant 70% increase in defect detection efficiency compared to traditional visual inspection methods. The AI-powered systems operate at an impressive 400–600 bottles per minute without requiring manual pre-programming for defect identification.

Yuting Shao, director at Xin Weisheng, said the collaboration highlights India’s critical role in the global pharma supply chain and applauded Nandani’s commitment to quality through automation adoption.

Dr Anil Kharia, director at Nandani Medical Laboratories, noted the importance of integrating cutting-edge automation to maintain batch consistency and regulatory standards as the company expands its global reach.

With installations across multiple continents, Xin Weisheng continues to invest in AI, machine learning, and automation technologies to help pharma manufacturers meet evolving quality standards and increase operational efficiency.